Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $92.18 Average PT from Analysts

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has received a consensus recommendation of “Buy” from the ten research firms that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $89.89.

ARWR has been the topic of several recent research reports. Chardan Capital reduced their price objective on Arrowhead Pharmaceuticals from $97.00 to $94.00 and set a “buy” rating on the stock in a research report on Friday, August 6th. HC Wainwright increased their price objective on Arrowhead Pharmaceuticals from $95.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, August 10th. SVB Leerink increased their price objective on Arrowhead Pharmaceuticals from $44.00 to $45.00 and gave the company a “market perform” rating in a research report on Tuesday. Finally, TheStreet upgraded Arrowhead Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Thursday, November 4th.

In other news, CEO Christopher Richard Anzalone sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, October 22nd. The stock was sold at an average price of $65.63, for a total value of $3,281,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Adeoye Y. Olukotun sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, September 13th. The shares were sold at an average price of $63.76, for a total value of $318,800.00. The disclosure for this sale can be found here. Insiders have sold a total of 89,500 shares of company stock valued at $5,945,295 over the last 90 days. 3.50% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of the stock. Great West Life Assurance Co. Can increased its position in Arrowhead Pharmaceuticals by 0.6% during the 2nd quarter. Great West Life Assurance Co. Can now owns 40,075 shares of the biotechnology company’s stock valued at $3,318,000 after buying an additional 239 shares in the last quarter. Moneta Group Investment Advisors LLC increased its position in Arrowhead Pharmaceuticals by 3.8% during the 2nd quarter. Moneta Group Investment Advisors LLC now owns 6,822 shares of the biotechnology company’s stock valued at $565,000 after buying an additional 247 shares in the last quarter. Fulton Bank N.A. increased its position in Arrowhead Pharmaceuticals by 6.5% during the 2nd quarter. Fulton Bank N.A. now owns 4,076 shares of the biotechnology company’s stock valued at $337,000 after buying an additional 249 shares in the last quarter. Sound Income Strategies LLC increased its position in Arrowhead Pharmaceuticals by 36.8% during the 2nd quarter. Sound Income Strategies LLC now owns 930 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 250 shares in the last quarter. Finally, Itau Unibanco Holding S.A. bought a new position in Arrowhead Pharmaceuticals during the 2nd quarter valued at approximately $26,000. 63.54% of the stock is owned by institutional investors.

NASDAQ ARWR traded up $3.15 during trading on Thursday, reaching $74.04. The company’s stock had a trading volume of 590,632 shares, compared to its average volume of 741,581. The stock has a market capitalization of $7.72 billion, a PE ratio of -60.20 and a beta of 1.14. The firm has a fifty day moving average of $67.29 and a 200 day moving average of $69.47. Arrowhead Pharmaceuticals has a one year low of $56.05 and a one year high of $93.66.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Sunday, November 21st. The biotechnology company reported ($0.61) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.65). Arrowhead Pharmaceuticals had a negative net margin of 116.97% and a negative return on equity of 28.00%. During the same period in the prior year, the business earned ($0.48) EPS. As a group, equities analysts forecast that Arrowhead Pharmaceuticals will post -0.79 earnings per share for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R.

Recommended Story: Certificate of Deposit (CD)

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.